Aldapt Mohmood B, Kassem Nancy, Al-Okka Randa, Ghasoub Rula, Soliman Dina, Abdulla Mohammad A, Mudawi Deena, Ibrahim Feryal, Yassin Mohamed A
Resident, Internal Medicine, Hamad Medical Corporation (HMC), Doha, Qatar.
Clinical Pharmacist, National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar.
Acta Biomed. 2018 Apr 3;89(3-S):33-37. doi: 10.23750/abm.v89i3-S.7218.
We present a rather uncommon side effect observed in a 20-year-old man with acute promyelocytic leukemia during treatment with ATRA. He developed a high platelet counts reaching up to 1655×10⁹/L on day 29 of ATRA treatment, and started to recover spontaneously on day 33 of treatment, without any change in ATRA, or adding any cytoreduction therapy. No complications associated with thrombocytosis were observed. IL-6 seems to play an important role in the pathogenesis of the thrombocytosis induced by ATRA. However, it is unclear what are the precipitating factors for this rare phenomenon and whether it is caused by certain predisposing factors that might be related to patient's, disease pathogenesis or other unknown factors.
我们报告了一名20岁急性早幼粒细胞白血病男性患者在使用全反式维甲酸(ATRA)治疗期间出现的一种相当罕见的副作用。在ATRA治疗第29天时,他的血小板计数升高,最高达到1655×10⁹/L,并在治疗第33天时开始自发恢复,在此期间未改变ATRA治疗方案,也未加用任何细胞减灭治疗。未观察到与血小板增多相关的并发症。白细胞介素-6似乎在ATRA诱导的血小板增多症发病机制中起重要作用。然而,尚不清楚这种罕见现象的诱发因素是什么,以及它是否由可能与患者、疾病发病机制或其他未知因素相关的某些易感因素引起。